In the past week, UNCY stock has gone down by -6.72%, with a monthly decline of -19.85% and a quarterly plunge of -69.17%. The volatility ratio for the week is 29.62%, and the volatility levels for the last 30 days are 14.82% for Unicycive Therapeutics Inc The simple moving average for the past 20 days is -15.81% for UNCY’s stock, with a -63.26% simple moving average for the past 200 days.
Is It Worth Investing in Unicycive Therapeutics Inc (NASDAQ: UNCY) Right Now?
UNCY has 36-month beta value of 2.38. Analysts have mixed views on the stock, with 0 analysts rating it as a “buy,” 0 as “overweight,” 0 as “hold,” and 0 as “sell.”
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
The public float for UNCY is 83.54M, and currently, short sellers hold a 1.60% ratio of that float. The average trading volume of UNCY on August 19, 2024 was 1.98M shares.
UNCY) stock’s latest price update
The stock of Unicycive Therapeutics Inc (NASDAQ: UNCY) has increased by 3.75 when compared to last closing price of 0.31.Despite this, the company has seen a loss of -6.72% in its stock price over the last five trading days. globenewswire.com reported 2024-08-14 that – On Track to Submit OLC New Drug Application (NDA) by End of August 2024 – LOS ALTOS, Calif., Aug. 14, 2024 (GLOBE NEWSWIRE) — Unicycive Therapeutics, Inc. (Nasdaq: UNCY) (the “Company” or “Unicycive”), a clinical-stage biotechnology company developing therapies for patients with kidney disease, today announced its financial results for the three months ended June 30, 2024, and provided a business update.
Analysts’ Opinion of UNCY
Many brokerage firms have already submitted their reports for UNCY stocks, with Piper Sandler repeating the rating for UNCY by listing it as a “Overweight.” The predicted price for UNCY in the upcoming period, according to Piper Sandler is $9 based on the research report published on April 04, 2024 of the current year 2024.
UNCY Trading at -33.60% from the 50-Day Moving Average
After a stumble in the market that brought UNCY to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -82.37% of loss for the given period.
Volatility was left at 14.82%, however, over the last 30 days, the volatility rate increased by 29.62%, as shares sank -18.52% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading -57.04% lower at present.
During the last 5 trading sessions, UNCY fell by -3.75%, which changed the moving average for the period of 200-days by -42.00% in comparison to the 20-day moving average, which settled at $0.3771. In addition, Unicycive Therapeutics Inc saw -63.05% in overturn over a single year, with a tendency to cut further losses.
Stock Fundamentals for UNCY
Current profitability levels for the company are sitting at:
- 106.48 for the present operating margin
- 2.64 for the gross margin
The net margin for Unicycive Therapeutics Inc stands at 107.88. The total capital return value is set at -0.91. Equity return is now at value -700.45, with -86.30 for asset returns.
Based on Unicycive Therapeutics Inc (UNCY), the company’s capital structure generated 1.47 points at debt to capital in total, while cash flow to debt ratio is standing at -0.46. The debt to equity ratio resting at -3.14. The interest coverage ratio of the stock is -5771.2.
Currently, EBITDA for the company is -20.49 million with net debt to EBITDA at -0.18. When we switch over and look at the enterprise to sales, we see a ratio of -131.97. The liquidity ratio also appears to be rather interesting for investors as it stands at 3.37.
Conclusion
To put it simply, Unicycive Therapeutics Inc (UNCY) has had a bad performance in recent times. Analysts have a mixed opinion on the stock, with some rating it as a “buy” and others as a “hold”. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.
